专利检索 ap:("The Broad Institute, Inc." OR "Dana-Farber Cancer Institute, Inc." OR "The General Hospital Corporation") AND inv:"Ute E. Burkhardt" 第 1 页

1.

发明申请
METHODS FOR PROFILING THE T-CEL- RECEPTOR REPERTOIRE 有权

公开(公告)号：US20210379168A1

公开(公告)日：2021-12-09

申请号：US17217864

申请日：2021-03-30

申请人： The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , The General Hospital Corporation

发明人： Nir Hacohen , Catherine Ju-Ying Wu , Edward F. Fritsch , Ute E. Burkhardt

IPC分类号： A61K39/00 , C12N15/10 , A61K35/17 , C12Q1/6881 , G01N33/569

摘要： The present disclosure relates to methods for profiling subject specific and personalized T cell receptor (TCR) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of T cell receptors to subject specific neoantigens. In addition, the techniques herein may identify the antigenic targets of T cell receptors in the context of tumor neoantigens. Moreover, the present disclosure enables the discovery of T cell targets in numerous diseases, with implications for understanding the basic mechanisms of the mammalian immune response and for developing antigen-specific diagnostic markers and therapies. Finally, cloned TCRs can be used to formulate personalized immunotherapies for those inflicted with a disease, such as cancer.

2.

发明授权
Methods for profiling the t cell repertoire 有权

公开(公告)号：US10993997B2

公开(公告)日：2021-05-04

申请号：US15537785

申请日：2015-12-21

申请人： The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , The General Hospital Corporation

发明人： Nir Hacohen , Catherine Ju-Ying Wu , Edward F. Fritsch , Ute E. Burkhardt

IPC分类号： C07K16/18 , G01N33/68 , G01N33/50 , A61K39/00 , C12N15/10 , A61K35/17 , C12Q1/6881 , G01N33/569

摘要： The present disclosure relates to methods for profiling subject specific and personalized T cell receptor (TCR) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of T cell receptors to subject specific neoantigens. In addition, the techniques herein may identify the antigenic targets of T cell receptors in the context of tumor neoantigens. Moreover, the present disclosure enables the discovery of T cell targets in numerous diseases, with implications for understanding the basic mechanisms of the mammalian immune response and for developing antigen-specific diagnostic markers and therapies. Finally, cloned TCRs can be used to formulate personalized immunotherapies for those inflicted with a disease, such as cancer.